Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

  • Views:

    Views Icon 23489
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 23489
  • Likes:

    Heart Icon 7
Part 4

of 6

Panel discussion moderated by John Eikelboom

John Eikelboom

Overview

In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.

Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

  • Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
  • Interpret safety and cardiovascular data from RCTs in the context of real-world experience
  • Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
  • Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

  • Cardiologists
  • Interventional Cardiologists

More from this programme

Faculty biographies